Maria Fleseriu - Concepedia

Author

Maria Fleseriu

Oregon Health & Science University ORCID

Also Known As

Biermasz, Nienke, Fleseriu M, Fleseriu, M, Fleseriu, Maria, Henry Fein, M Fleseriu, M Fleşeriu, M. Fleseriu, Marcello D. Bronstein, Maria Fleseriu

518

Publications

14.1K

Citations

H-Index

Concepts

All Affiliations

Oregon Health & Science University Neurological Surgery Massachusetts General Hospital University of Naples Federico II Novartis (Switzerland)

About

Maria Fleseriu is an author at Oregon Health & Science University specializing in medicine, endocrinology, and adrenal disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	37	2.2K
2	Health Sciences	4	4	140
3	Allergy	3	3	222
4	Public Health	2	2	52
5	Social Sciences	1	1	55

Maria Fleseriu

103

Publications

Citations

H-Index

Page 1

	Year	Citations
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline Maria Fleseriu, Ibrahim A. Hashim, Niki Karavitaki, The Journal of Clinical Endocrinology & Metabolism	2016	898
Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome Maria Fleseriu, Beverly M. K. Biller, James W. Findling, The Journal of Clinical Endocrinology & Metabolism	2012	472
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial Mônica R. Gadelha, Marcello D. Bronstein, Thierry Brue, The Lancet Diabetes & Endocrinology MedicineNeurologyPasireotide Versus	2014	395
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study Annamaria Colao, Marcello D. Bronstein, Pamela U. Freda, The Journal of Clinical Endocrinology & Metabolism	2014	389
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update Andrea Giustina, Ariel Barkan, Albert Beckers, The Journal of Clinical Endocrinology & Metabolism	2019	342
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase Rosario Pivonello, Maria Fleseriu, John Newell‐Price, The Lancet Diabetes & Endocrinology Linc 3Withdrawal PhaseMedicineClinical TrialsPharmacotherapy	2020	198
LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study Xavier Bertagna, Rosario Pivonello, Maria Fleseriu, The Journal of Clinical Endocrinology & Metabolism	2013	183
Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in<i>AIP</i>Mutation Carriers Laura C. Hernández‐Ramírez, Plamena Gabrovska, Judit Dénes, The Journal of Clinical Endocrinology & Metabolism	2015	167
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial André Lacroix, Feng Gu, Wilson Gallardo, The Lancet Diabetes & Endocrinology Month Clinical TrialUrologyPituitary DiseaseAdrenal DiseaseEndocrinology	2017	163
Consensus on criteria for acromegaly diagnosis and remission Andrea Giustina, Nienke R. Biermasz, Felipe F. Casanueva, Pituitary	2023	156

Page 1